Showing 1294 results
- Media Release /SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,…
- Story /
A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.
- Story /
Compound offers a potential tool for fighting drug-resistant malaria parasites.
- Key Release /Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel,…
- Media Release /Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
- Media Release /Pivotal overall survival data for investigational compound PKC412 (midostaurin) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia Presentations highlight new CTL019 data in…
- Media Release /Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program…
- Media Release /– Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of…
- Media Release /Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
- Media Library /
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 130
- › Next page